Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Wolf, Jürgen; Seto, Takashi; Han, Ji‐Youn; Reguart, Noemı́; B. Garon, Edward; J.M. Groen, Harry; S.W. Tan, Daniel; Hida, Toyoaki; J.A. de Jonge, Maja; Orlov, Sergey; F. Smit, Egbert; Souquet, Pierre-Jean; Vansteenkiste, Johan; J. Hochmair, Maximilian; Felip, Enriqueta; Nishio, Makoto; Thomas, Michael; Ohashi, Kadoaki; Toyozawa, Ryo; R. Overbeck, Tobias; de Marinis, Filippo; Min Kim, Tae; Laack, Eckart; Robeva, Anna; Le Mouhaër, Sylvie; Waldron-Lynch, Maeve; Sankaran, B.; Alejandro Balbin, O.; Cui, Xiaoming; Giovannini, Monica; Akimov, Mikhail; S. Heist, Rebecca

doi:10.1056/nejmoa2002787

Public

Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Sep 2, 2020

Authors:

Jürgen Wolf

Takashi Seto

Ji‐Youn Han

Abstract

BACKGROUND: amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation. METHODS: amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice dail...

Subject

Exon

Lung cancer

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!